At the European NeoAg Summit, we bring together the leading pharma and biotech companies to discuss: Reducing the discordance between various neoantigen prediction methods / Maximising the immune response to neoantigens / Shortening the needle-to-needle time of personalised cancer immunotherapy / Navigating the evolving regulatory landscape to faster approval
This program is ideally suited for North American-based Junior Faculty, Fellows, and Postdoctoral Researchers (MDs, DOs, and PhDs) who are pursuing a career in academic research by conducting basic science, translational, and/or clinical research using immuno-oncology strategies directed at solid tumor or hematologic malignancies.
Since 1989, Cancer Progress is the only oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives in two days of interactive dialogue. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking throughout the meeting during breaks, luncheons, reception and dinner combine to make this a highly impactful conference.
Our 30th Annual Meeting on May 7-8, 2019 will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference.
The American Association of Immunologists (AAI) is dedicated to advancing the field of immunology and fostering development opportunities for researchers at every career stage. Its members work together to address common interests and push forward the boundaries of knowledge. IMMUNOLOGY 2019 is the leading annual all-immunology event worldwide.
This two-day symposium will convene leading experts in cancer immunotherapy to discuss cutting-edge findings in the broad area of combination therapies, including checkpoint inhibitors and cellular therapies. Particular emphasis will be given to the biological mechanisms underlying combination hypotheses, bispecific antibodies and other emerging modalities for delivery of combination therapies, as well as a discussion of the importance of biomarkers and effective clinical trial design.
Over 60 presentations will provide the latest case studies across key therapeutic areas such as T-cell therapy, bispecific antibodies, cancer vaccines, checkpoint inhibitors and microbiome-based therapeutics. Further talks look at genomic strategies for cancer immunotherapy, as well as personalising cancer treatments. To enhance the interactivity of the programme, we have also incorporated an increased amount of discussion opportunities through panels, roundtables and workshops on hot topics in the field.
For further information about the programme, registration and discounts please contact email@example.com.
For its 17th edition, the CIMT program committee is preparing plenary sessions from pre-clinical research to clinical development on the topics of neoantigens, cellular therapy, improving immunity, tumor microenvironment, regulatory research and immunoguiding. The plenary sessions will be complemented by a poster exhibit and selected poster short talk sessions, as well as industry symposia and industry exhibits.
The Annual Meeting brings together more than 32,000 oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field.
This Nature conference brings together leading experts from around the globe to discuss a range of immunotherapeutic approaches and the immunological basis that informs these efforts. Besides covering immune checkpoint inhibitors and cellular therapies, sessions will explore vaccination approaches and oncolytic therapy, the role of innate immune cells and their potential for immunotherapy, the effect of the microbiota on immunotherapy and how to exploit immunometabolism to modulate immune responses in cancer and beyond.
Most critical scientifically cutting edge and investment-attractive topics will be discussed at the meeting that includes two well established and two new congresses: 15th Annual Biomarker World Congress | 18th Annual World Preclinical Congress | Inaugural Immuno-Oncology Pharma Congress | Inaugural Digital Health Pharma Congress.
World Pharma Week will bring together a unique and international mix of large and medium pharmaceutical and biotech companies, CROs, leading universities and clinical research institutions, emerging companies and tool providers—making it a perfect meeting-place to share experience, foster collaborations across industry and academia, and evaluate emerging technologies.
An ideal conference for researchers, industrials, and clinicians to exchange ideas about therapeutic antibodies. This year's edition will focus on Harnessing the Immune System with mAbs, a major topic chosen by the AIS Scientific Advisory Board constituted by Pierre Fabre, Servier, IRCM, MabDesign, Sanofi, OSE Immunotherapeutics, LFB, CEPR, IGMM, LabEx MabImprove, and Tours University. The AIS2019 will cover the multifaceted mechanisms underlying antibody-mediated immune responses. More than 300 experts are expected this year.
This event will be conducted in French.
Les Master Classes de l’immunothérapie est le Grand Rendez-vous Formation en immunothérapie et bioproduction de l’année. Une journée de formations inédites et interactives est organisée. Vous accéderez également à une conférence d’ouverture sur les Biomarqueurs, un cocktail gala, du networking et des ateliers technologiques animés par des industriels.
Les thématiques de formation sont sélectionnées selon les enjeux de la filière : brevet des biomédicament ; Quality by Design ; les Bioassay dans le développement d’un biomédicament ; Contrôle qualité et analyse des mAbs ; Méthode analytique pour évaluer la développabilité de son biomédicament ; Initiation aux CAR T-cells ; Procédés perfusion appliqués à la production d’anticorps ; Purification des mAbs ; Prérequis réglementaires pour entrer en développement clinique.
This AACR Special Conference on Immune Cell Therapies for Cancer will focus on the successes and challenges of utilizing a patient’s immune cells to recognize and attack their own cancerous cells. The organizers have designed a meeting that will maximize collaboration between researchers, clinicians, and industry professionals.
A summit focused on accelerating to market the next generation of potent, safe and efficacious CAR-TCR therapies for solid tumor indications, whilst ensuring the accessibility and commercial delivery of currently approved life-changing CAR-TCR therapies to patients around the world.
Topics: Cancer prevention and life style factors in oncoimmunology; Combination therapies with immune checkpoint blockers; T cell exhaustion – mechanisms of resistance; Immunotherapies, non-cell-based; Immunotherapies, cell based; New targets and concepts; Tumor antigens; Vaccination strategies; New trends in technology & informatics; TME analysis; Onco- and immunometabolism; Microbiota in oncoimmunology
The ESMO Congress is the appointment in Europe for clinicians, researchers, patient advocates, journalists and the pharmaceutical industry from all over the world to get together, learn about the latest advances in oncology and translate science into better cancer patient care.
The 34th Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2019) scheduled to take place Nov. 6-10, 2019, at the Gaylord National Hotel & Convention Center in National Harbor, Md.
The hallmark of this series is also to encourage the effective exchange of ideas between basic cancer immunologists, non-immunologists, and clinical oncologists in order to develop approaches that translate to outcomes. This year’s program will feature international leaders in the field, who will expand our knowledge of the microbiome; adverse immunological events; imaging and other new technologies; genetics and epigenomics of immuno-oncology; and immunological signaling pathways. These world-renowned oncologists and researchers will offer their insights on novel cell therapies, biomarkers, vaccines and adjuvants, all in the pursuit of understanding tumor evolution and creating better treatments.
Join workshop Course Directors Drs. George D. Demetri, Susan Band Horwitz, and Pasi A. Jänne for an intensive introduction to translational cancer research. This week-long workshop will provide basic scientists with a better understanding of translational research and strategies for adapting their research for maximum clinical impact. Apply by April 30.